TERAZOSIN EVALUATION AS MALE LUTS TREATMENT USING IPSS SUB-SCORING RATIO
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: To evaluate the improvement of Lower Urinary Tract Symptoms (LUTS) in males treated with terazosin based on sub scoring ratio of the International Prostatic Symptoms Score (IPSS). Material & Method: Sixty eight male with LUTS subjected to terazosin 1 mg daily and divided into two groups based on IPSS sub scoring ratio. After 3 months improvement of the symptoms were evaluated using the IPSS. Data analysis was done using paired T-test. The conclusion was based on significance level p<0,05. Results: The IPSS score was improving on both failure to void group (IPSS- v/s >1) and failure to store group (IPSS- v/s ≤1) after 3 months of Terazosin therapy (mean= 9,56 versus 6,94). Statistically superior improvement was observed on failure to voiding group (p=0,0003) (95CI:1,30-3,93). Conclusion: Terazosin is best given to male LUTS with IPSS- v/s >1 although both groups respond well.Keywords:International prostatic symptoms score, sub score, failure to voiding, failure to storage, male, lower urinary tract symptoms.
##plugins.themes.bootstrap3.article.details##
Wei JT, Calhoun E, Jacobsen SJ. Urologic disease in America project: Benign prostate hyperplasia. J Urol. 2005; 173: 1256-61.
Naslund MJ, Gilsenan AW, Midkiff KD. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007; 61(9): 1437-45.
De la Rosette JJ, Witjes WP. Relationship between lower urinary tract symptoms and bladder outlet obstruction. Neurourol. Urodyn. 1998; 17(2): 99–108.
Chapple C, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on bladder. Eur Urol. 2006; 49(4): 651-8.
Roehrborn CG. Benign prostate hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. Campbell-Walsh Urology. 10th ed. Philadelphia: WB Saunders; 2011. p. 2584-5.
Liao CH, Chung SD, Kuo HC. Diagnostic value of international prostate symptom score voiding-to-storage subscore ratio in male lower urinary tract symptoms. Int J Clin Pract. 2011; 65(5): 552-8.
Wein AJ. Pathophysiology and classification of lower urinary tract dysfunction: Overview. Campbell-Walsh Urology. 10th ed. Philadelphia: WB Saunders; 2011. p. 1834-46.
Roehrborn CG. Clinical management of lower urinary tract symptoms with combined medical therapy. BJU Int. 2008; supp 2: 13-7.
Djavan B, Marberger M. A meta-analysis of the efficacy and tolerability of alfa-1 adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999; 36: 1-13.
Barkin J, Guimaraes M. Alfa blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol. 2003; 44: 461-66.
Michel MC, Vrydag W. α1-, α2- and β-adrenoceptor in the urinary bladder, urethra and prostate. BJ Pharm. 2006; 147: 88-119.
Djavan B, Chapple C, Milani S. State of the art of the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. J Urol; 64. p. 1081-8.
Hillman AL, Schwartz JS, Willian MK. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urol. 1996; 47(2): 169-78.
Abrams P, Chapple C, Khoury S. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009; 181(4): 1779-87.
McNicholas T, Kirby R. Evaluation and nonsurgical management of benign prostate hyperplasia. Campbell-Walsh Urology. 10th ed. Philadelphia: WB Saunders; 2011. p. 2611-53.